Psychopharmacology

, Volume 81, Issue 4, pp 359–362 | Cite as

Variation in oro-facial tardive dyskinesia during depot antipsychotic drug treatment

  • Thomas R. E. Barnes
  • David H. Wiles
Rapid Communications

Abstract

Oro-facial (tardive) dyskinesia, occurring in patients on long-term antipsychotic (dopamine antagonist) medication, can be suppressed temperarily by increasing the drug dose. Lowering the dose can exacerbate the condition. In patients receiving regular fluphenazine decanoate (FPZ) and flupenthixol decanoate (FPT) injections, characteristic profiles of the fluctuations in plasma level concentrations, occurring during the injection interval, have been demonstrated. The possible effects of these relatively predictable plasma level changes on the severity of oro-facial dyskinesia, and parkinsonism, were investigated. Regular assessment of oro-facial dyskinesia throughout the injection interval was carried out in six patients receiving FPZ and two patients receiving FPT. In both groups, changes were observed in the severity of oro-facial dyskinesia consistent with the expected effects of drug level fluctuations. The main implication of this finding is that, in investigations of tardive dyskinesia in patients receiving depot medication, ratings should be carried out at a standard time relative to injections.

Key words

Tardive dyskinesia Fluphenazine decanoate Flupenthixol decanoate Depot neuroleptics Plasma concentration Parkinsonism 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ayd FJ (1975) The depot fluphenazines: a reappraisal after 10 years' clinical experience. Am J Psychiatry 132:491–500Google Scholar
  2. Barnes TRE, Kidger T, Gore SM (1983) Tardive dyskinesia: a 3-year follow-up study. Psychol Med 13:71–81Google Scholar
  3. Barnes TRE, Trauer T (1982) Reliability and validity of a tardive dyskinesia videotape rating technique. Br J Psychiatry 140:508–515Google Scholar
  4. Chang SS, Javaid JI, Dysken MW, Casper RC, Janicak PJ, Davis JM (1981) Pharmacokinetic study of fluphenazine decanoate. Presented at IIIrd World Congress of Biological Psychiatry, Stockholm (abstract F72)Google Scholar
  5. Chouinard G, Annable L, Ross-Chouinard A (1982) Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect. Am J Psychiatry 139:312–318Google Scholar
  6. Curry SH, Whelpton R, De Schepper PJ, Vranckx S, Schiff AA (1978) Plasma fluphenazine concentrations after injection of long-acting esters. Lancet I:1217–1218Google Scholar
  7. Curry SH, Whelpton R, De Schepper PJ, Vranckx S, Schiff AA (1979) Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration in man. Br J Clin Pharmacol 7:325–331Google Scholar
  8. Jørgensen A (1978) A sensitive and specific radioimmunoassay for cis (z)-flupentixol in human serum. Life Sci 23:1533–1542Google Scholar
  9. Jørgensen A (1980) Pharmacokinetic studies in volunteers of intravenous and oral cis (z)-flupentixol and intramuscular cis (z)-flupentixol decanoate in viscoleo. Eur J Clin Pharmacol 18:355–360Google Scholar
  10. Jørgensen A, Overø KF (1980) Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics; III serum levels. Acta Psychiatr Scand 279:41–54Google Scholar
  11. Kane JM, Smith JM (1982) Tardive dyskinesia: prevalence and risk factors 1959–1979. Arch Gen Psychiatry 39:473–481Google Scholar
  12. Lamb P, Mindham RHS, Ezzat MA (1976) Parkinsonism induced by fluphenazine decanoate. Lancet 1:484Google Scholar
  13. MacKay AVP, Sheppard GP (1979) Pharmacotherapeutic trials in tardive dyskinesia. Br J Psychiatry 135:489–499Google Scholar
  14. Marsden CD, Tarsy D, Baldessarini RJ (1975) Spontaneous and drug-induced movement disorders in psychotic patients. In: Benson DF, Blumer D (eds) Psychiatric aspects of neurological disease. Grune and Stratton, New York, pp 219–265Google Scholar
  15. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal sideeffects. Acta Psychiatr Scand 212(44):11–19Google Scholar
  16. Tune LE, Creese I, Coyle JT, Pearson G, Snyder SH (1980) Low neuroleptic serum levels in patients receiving fluphenazine decanoate. Am J Psychiatry 137:80–82Google Scholar
  17. Wiles DH (1979) Tardive dyskinesia and depot fluphenazine. Br J Psychiatry 135:382–383Google Scholar
  18. Wiles DH, Franklin M (1978) Radioimmunoassay for fluphenazine in human plasma. Br J Clin Pharmacol 5:265–268Google Scholar
  19. Wiles DH, Gelder MG (1979) Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate. Br J Clin Pharmacol 8:565–570Google Scholar

Copyright information

© Springer-Verlag 1983

Authors and Affiliations

  • Thomas R. E. Barnes
    • 1
  • David H. Wiles
    • 2
  1. 1.Department of Psychiatry StGeorge's Hospital Medical School, Cranmer TerraceLondonUK
  2. 2.Crichton Royal HospitalDumfriesScotland, UK

Personalised recommendations